Discounted Cash Flow (DCF) Analysis Levered
Pressure BioSciences, Inc. (PBIO)
$0.23
+0.03 (+15.29%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 2.46 | 1.81 | 1.22 | 2 | 1.73 | 1.69 | 1.66 | 1.62 | 1.59 | 1.55 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -5.70 | -6.33 | -4.88 | -4.87 | -4.48 | -5.02 | -4.91 | -4.81 | -4.71 | -4.61 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | - | -0.02 | -0 | -0.12 | -0.02 | -0.04 | -0.04 | -0.04 | -0.03 | -0.03 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -5.70 | -6.35 | -4.88 | -4.99 | -4.50 | -5.06 | -4.95 | -4.85 | -4.74 | -4.64 |
Weighted Average Cost Of Capital
| Share price | $ 0.23 |
|---|---|
| Beta | 0.675 |
| Diluted Shares Outstanding | 11,058.36 |
| Cost of Debt | |
| Tax Rate | -4.65 |
| After-tax Cost of Debt | 50.85% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 7.989 |
| Total Debt | 20.53 |
| Total Equity | 2,543.42 |
| Total Capital | 2,563.95 |
| Debt Weighting | 0.80 |
| Equity Weighting | 99.20 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 2.46 | 1.81 | 1.22 | 2 | 1.73 | 1.69 | 1.66 | 1.62 | 1.59 | 1.55 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.70 | -6.33 | -4.88 | -4.87 | -4.48 | -5.02 | -4.91 | -4.81 | -4.71 | -4.61 |
| Capital Expenditure | - | -0.02 | -0 | -0.12 | -0.02 | -0.04 | -0.04 | -0.04 | -0.03 | -0.03 |
| Free Cash Flow | -5.70 | -6.35 | -4.88 | -4.99 | -4.50 | -5.06 | -4.95 | -4.85 | -4.74 | -4.64 |
| WACC | ||||||||||
| PV LFCF | -4.67 | -4.22 | -3.81 | -3.44 | -3.11 | |||||
| SUM PV LFCF | -19.26 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 8.33 |
| Free cash flow (t + 1) | -4.73 |
| Terminal Value | -74.80 |
| Present Value of Terminal Value | -50.14 |
Intrinsic Value
| Enterprise Value | -69.39 |
|---|---|
| Net Debt | 20.53 |
| Equity Value | -89.92 |
| Shares Outstanding | 11,058.36 |
| Equity Value Per Share | -0.01 |